GlaxoSmithKline has accused fellow pharma giant Pfizer of using its tech to make a rival RSV vaccine.
The British-based firm claims Pfizer — the creator of Viagra and Covid jabs — copied components and methods created by GSK years earlier to make its own jab against the cold-causing virus.
Both GSK’s jab (Arexvy) and Pfizer’s (Abrysvo) have been approved in the US, while UK regulators have only approved the option made by GSK.
The companies are in a race for their competing vaccines to be rolled out across the globe, in the hopes of making billions in revenue a year as nations strive to slash hospitalisations and deaths.
Both GSK’s jab, Arexvy, and Pfizer’s, Abrysvo, have been approved in the US, while UK regulators have only approved the option made by GSK
The New York-based company copied components and methods created by GSK years earlier to make its own jab against the cold-causing virus, 팔팔정구구정퀵배송 GSK says
On May 3, the US Food and Drug Administration (FDA) approved GSK’s Arexvy for use in the over-60s. The UK followed suit a month later.
On May 31, the US gave the green light to Pfizer’s Abrysvo for the same cohort.
Following the US approval of Abrysvo, 시알리스비아그라차이 Pfizer said it would have sufficient supplies of the vaccine to dish out by the autumn.
In a lawsuit filed in a federal court in Delaware yesterday, GSK said Pfizer infringes its patent by making, using, selling and importing Abrysvo in the US.
A patent is a certificate that recognises a new invention and lets the creator take legal action against a company that makes, uses or sells it without permission.
Arexvy works by exposing the immune system to proteins from the surface of the virus, which triggers the body to make antibodies that can fight-off RSV